ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)

This DANCR-mediated regulation promotes the interaction between ABL2 and the cytoskeletal regulator cortactin, which leads to activation of the SSH1-cofilin pathway and then facilitates the formation of lamellipodia, cytoskeletal reorganization and the metastatic ability of tumors. In summary, our findings delineate the DANCR/miR-125a-5p/ABL2/cofilin axis as a critical regulator of cytoskeletal dynamics in neuroblastoma metastasis, offering novel insights for the diagnosis and therapeutic targeting of high-risk neuroblastoma.

The conformational dynamics of these protein-ligand complexes were further confirmed by principal component analysis and free-energy landscape analysis. Overall, the findings suggest that Pachyrrhizin and Lupinisoflavone K may serve as potential ABL2 inhibitors, warranting further in vitro and in vivo validation.

P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jun 2027 --> Aug 2027

Together, these findings show that IHG is a fusion driven tumor of the very young that is survivable even after progression. While optimal primary therapy for patients with IHG has yet to be established, the findings of this meta-analysis suggest treatment should focus on lowering surgical morbidity and improving its success.

Toxicological projections indicated few side effects, confirming their potential as medication candidates. Inverse-docking analysis of the five potent compounds 6a-c, 6e, and 6f against 12 selected protein tyrosine kinases (PTKs) and cyclin-dependent kinases (CDKs) revealed good docking scores, strong interaction patterns, and potential inhibitory effects, particularly against ABL1, ABL2, CDK4, and CDK6 enzymes, suggesting these compounds as promising candidates for further drug development.

P3, N=154, Recruiting, Nanfang Hospital, Southern Medical University

The method requires only 10 ng of RNA input, delivers results in 3 days (vs. 7-14 days for conventional methods), and reduces costs by 50%. By offering rapid and accurate fusion detection, PACLseq has the potential to significantly improve diagnostic efficiency, facilitate timely treatment decisions, and enhance patient outcomes in the management of Ph-like ALL.

SBS, a Pythagorean-based metric combining operative time and aBL, accurately predicts complications. The SBS-based model offers strong predictive utility for risk stratification.

Cytotoxicity assays in resistant melanoma cells showed IC50 values of 12.3 μM (A375) and 20.1 μM (A375-R), demonstrating potency comparable to vemurafenib...Furthermore, the apoptotic efficacy of 8h demonstrated a significant increase in the percentage of late apoptotic cells, reaching 13.89 % in treated cells, in contrast to 0.15 % in untreated cells. In Silico ADME profiling indicated that the proposed compounds are suitable drug candidates.

This study demonstrates that PDCD4 modulates AF progression by regulating key genes and pathways involved in inflammation, fibrosis, and metabolic processes. Insights from transcriptome and single-cell analysis give a full knowledge of the molecular processes underlying AF and indicate PDCD4 as a possible therapeutic target.

In this study, we extended these in vitro findings to demonstrate similar sensitivity to the second-generation STAMP inhibitor, TERN-701, using ZC3HAV1::ABL2 ALL cells. Importantly, this suggests that, in the clinical setting, different asciminib binding site mutations may be anticipated with STAMP treatment for ABL2r ALL. Finally, we demonstrated the efficacy of both STAMP inhibitors against cells from patients with ZC3HAV1::ABL2 and asciminib as a novel treatment for ZC3HAV1::ABL2 disease in a preclinical in vivo study.

P1, N=12, Not yet recruiting, Washington University School of Medicine